🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Red Blood Cell Transfusion in ECMO - A Feasibility Trial

RecruitingNAAges 18 Years - anyAllAustralian and New Zealand Intensive Care Researc…
NCT05814094 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe cases of COVID-19). ECMO acts as a mechanical circulatory support temporarily replacing the function of the heart or lungs by oxygenating blood and removing carbon dioxide, allowing time for these organs to recover. Many critically ill patients, including those on ECMO, have an increased risk of bleeding and reduced production/increased destruction of red blood cells (RBCs). This can lead to anaemia (haemoglobin levels \<120 g/l), a condition where the body lacks enough healthy RBCs to carry enough oxygen to the body's tissues. Therefore, patients on ECMO frequently require RBC transfusion, with clinicians having to decide if administering an RBC transfusion (with

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients receiving ECMO * Age: 18 years or older Exclusion Criteria: * Contraindication to RBC transfusion (including known patient preference) * Limitations of care put in place either through patient wishes or the treating medical teams * ECMO treatment for more than 12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start is defined as the arrival time into the initial ICU. * The treating physician anticipates that ECMO treatment will cease before the end of tomorrow * Where the treating physician deems the study is not in the patient's best interest * Where the treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds * Patients actively listed for a solid organ transplant * Patients who are suspected or confirmed to be pregnant * Previous ECMO treatment during the same hospital admission
💊

What it tests

  • Red Blood Cell Transfusion
  • Red Blood Cell Transfusion
📍

Where

2 sites
Royal Prince Alfred Hospital
Camperdown, Australia
St Vincent's Health Sydney
Sydney, Australia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy